BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Apax Partners & Co. Leads Spin-Out of Biomarker Discovery Company Sense Proteomic Limited; Sense Proteomic Limited Spun Out of Procognia Limited by Apax Partners & Co. and its Management Team


6/5/2008 11:44:36 AM

Maidenhead, UK: June 4, 2008, Sense Proteomic Ltd. today announced its spin out and its creation as a biomarker discovery company. It will now be focussing on using its proprietary protein array platform to discover novel panels of auto-antibody biomarkers in cancer and autoimmune diseases. Sense Proteomic was previously a subsidiary of the biosciences tools business Procognia Ltd, whose other subsidiary was listed on the Tel-Aviv stock exchange in 2007.

Commenting on the deal, Amos Goren, of Apax, said, “Apax is pleased to be supporting the new management team of Sense Proteomic as they develop this exciting business. It is our belief that over the next few years growth in the diagnostic industry will revolutionise healthcare by enabling earlier and more targeted treatment of disease.”

Rachel Fallon Joint CEO said, “Apax’s support will allow us to accelerate our biomarker programmes to validate the strong data we already have in both autoimmune diseases and cancer. This will allow us to maintain our position as leaders in the field.”

Chris Lyddon, Sense Proteomic’s other Joint CEO, added “I am delighted that Apax has invested in Sense Proteomic, their support endorses both our technical approach and our business model”.

About Sense Proteomic Limited Sense Proteomic Limited is a biomarker discovery company utilising its proprietary protein array technology to discover and commercialise auto antibody biomarkers for cancer and autoimmune diseases.

About Apax Partners Apax Partners is one of the world's leading private equity investment groups, operating across Europe, Israel, the United States and Asia. With over 30 years of direct investing experience, Apax Partners' Funds provide long-term equity financing to entrepreneurs to build and strengthen world-class companies.

For information contact:
Sense Proteomic Limited
Chris Lyddon - Joint CEO
Tel +44 (0)1628 513 500
chris.lyddon@senseproteomic.com



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES